Rationale and design of the validation of bladder health instrument for evaluation in women (VIEW) protocol

For the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium

doi:10.1186/s12905-020-01136-w

Rationale and design of the validation of bladder health instrument for evaluation in women (VIEW) protocol

For the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Background: Bladder health is an understudied state and difficult to measure due to lack of valid and reliable instruments. While condition specific questionnaires assess presence, severity and degree of bother from lower urinary tract symptoms, the absence of symptoms is insufficient to assume bladder health. This study describes the methodology used to validate a novel bladder health instrument to measure the spectrum of bladder health from very healthy to very unhealthy in population based and clinical research. Methods: Three samples of women are being recruited: a sample from a nationally representative general population and two locally recruited clinical center samples—women with a targeted range of symptom severity and type, and a postpartum group. The general population sample includes 694 women, 18 years or older, randomly selected from a US Postal delivery sequence file. Participants are randomly assigned to electronic or paper versions of the bladder health instrument along with a battery of criterion questionnaires and a demographic survey; followed by a retest or a two-day voiding symptom diary. A total of 354 women around 7 clinical centers are being recruited across a spectrum of self-reported symptoms and randomized to mode of completion. They complete the two-day voiding symptom diary as well as a one-day frequency volume diary prior to an in-person evaluation with a standardized cough stress test, non-invasive urine flowmetry, chemical urine analysis and post void residual measurement. Independent judge ratings of bladder health are obtained by interview with a qualified health care provider. A total of 154 postpartum women recruited around 6 of the centers are completing similar assessments within 6–12 weeks postpartum. Dimensional validity will be evaluated using factor analysis and principal components analysis with varimax rotation, and internal consistency with Cronbach’s alpha. Criterion validity will be assessed using multitrait-multimethod matrix including correlations across multiple data sources and multiple types of measures. Discussion: We aim to validate a bladder health instrument to measure the degree of bladder health within the general population and among women (including postpartum) recruited from local clinical centers. Trial registration NCT04016298 Posted July 11, 2019 (https://www.clinicaltrials.gov/ct2/show/NCT04016298?cond=bladder+health&draw=2&rank=1).

Original language	English (US)
Article number	18
Journal	BMC Women's Health
Volume	21
Issue number	1
DOIs	https://doi.org/10.1186/s12905-020-01136-w
State	Published - Dec 2021

Bibliographical note

Funding Information:
The PLUS Research Consortium (aka Group Authorship) consists of the following members who contributed to this work. Linda Brubaker, MD, MS; Elizabeth Mueller, MD, MSME; Colleen Fitzgerald, MD, MS; Cecilla Hardacker, RN, MSN; Jennifer Hebert-Beirne, PhD; Missy Lavender, MBA; David Shoham, PhD; Alayne D. Markland, DO, MSc; Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM; Kathryn L. Burgio, PhD; Cora E. Lewis, MD; Gerald McGwin, PhD; Camille P. Vaughan, MD, MS; Beverly R. Williams, PhD; Emily S. Lukacz, MD; Sheila Gahagan, MD, MPH; Daphne Y. LaCoursiere, MD, MPH; Jesse Nodora, DrPH; Janis M. Miller, PhD, MSN; Lawrence Chin-I An, MD; Lisa Kane Low, PhD, MS, CNM; Diane K. Newman, DNP, CRNP; Amanda Berry, MSN, CRNP; C. Neill Epperson, MD; Heather Klusaritz, PhD, MSW; Kathryn H. Schmitz, PhD; Ariana L. Smith, MD; Ann E. Stapleton, MD; Jean F. Wyman, PhD; Siobhan Sutcliffe, PhD; Aimee S. James, PhD; Jerry Lowder, MD, MSc; Melanie R. Meister, MD, MSCI: Leslie M. Rickey, MD; Deepa Camenga, MD, MS; Shayna D. Cunningham, PhD; Jessica Lewis, PhD.; Tamara G. Bavendam MD, MS; Bernard L. Harlow, PhD and Kyle Rudser, PhD; Sonya S Brady, PhD; John Connett, PhD; Haitao Chu, MD, PhD; Melissa L. Constantine, PhD, MPaff; Cynthia S. Fok, MD, MPH; Todd Rockwood, PhD; Mary H. Palmer, PhD, RN.

Funding Information:
There are no financial conflicts directly related to this work. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) by cooperative agreements [grants U01DK106786, U01 DK106853, U01 DK106858, U01 DK106898, U01 DK106893, U01 DK106827, U01 DK106908, U01 DK106892]. Additional funding from: National Institute on Aging, NIH Office of Research on Women’s Health and the NIH Office of Behavioral and Social Sciences Research. NIH Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2021, The Author(s).

Keywords

Bladder
Health
Instrument
Measurement
Questionnaire
Scale
Validation

Publisher link

10.1186/s12905-020-01136-w

Find It

Find It at U of M Libraries

Cite this

@article{aa8ad40853b04ddd922734a88dca4f45,

title = "Rationale and design of the validation of bladder health instrument for evaluation in women (VIEW) protocol",

abstract = "Background: Bladder health is an understudied state and difficult to measure due to lack of valid and reliable instruments. While condition specific questionnaires assess presence, severity and degree of bother from lower urinary tract symptoms, the absence of symptoms is insufficient to assume bladder health. This study describes the methodology used to validate a novel bladder health instrument to measure the spectrum of bladder health from very healthy to very unhealthy in population based and clinical research. Methods: Three samples of women are being recruited: a sample from a nationally representative general population and two locally recruited clinical center samples—women with a targeted range of symptom severity and type, and a postpartum group. The general population sample includes 694 women, 18 years or older, randomly selected from a US Postal delivery sequence file. Participants are randomly assigned to electronic or paper versions of the bladder health instrument along with a battery of criterion questionnaires and a demographic survey; followed by a retest or a two-day voiding symptom diary. A total of 354 women around 7 clinical centers are being recruited across a spectrum of self-reported symptoms and randomized to mode of completion. They complete the two-day voiding symptom diary as well as a one-day frequency volume diary prior to an in-person evaluation with a standardized cough stress test, non-invasive urine flowmetry, chemical urine analysis and post void residual measurement. Independent judge ratings of bladder health are obtained by interview with a qualified health care provider. A total of 154 postpartum women recruited around 6 of the centers are completing similar assessments within 6–12 weeks postpartum. Dimensional validity will be evaluated using factor analysis and principal components analysis with varimax rotation, and internal consistency with Cronbach{\textquoteright}s alpha. Criterion validity will be assessed using multitrait-multimethod matrix including correlations across multiple data sources and multiple types of measures. Discussion: We aim to validate a bladder health instrument to measure the degree of bladder health within the general population and among women (including postpartum) recruited from local clinical centers. Trial registration NCT04016298 Posted July 11, 2019 (https://www.clinicaltrials.gov/ct2/show/NCT04016298?cond=bladder+health&draw=2&rank=1).",

keywords = "Bladder, Health, Instrument, Measurement, Questionnaire, Scale, Validation",

author = "{For the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium} and Lukacz, {Emily S.} and Constantine, {Melissa L.} and {Kane Low}, Lisa and Lowder, {Jerry L.} and Markland, {Alayne D.} and Mueller, {Elizabeth R.} and Newman, {Diane K.} and Rickey, {Leslie M.} and Todd Rockwood and Kyle Rudser",

note = "Funding Information: The PLUS Research Consortium (aka Group Authorship) consists of the following members who contributed to this work. Linda Brubaker, MD, MS; Elizabeth Mueller, MD, MSME; Colleen Fitzgerald, MD, MS; Cecilla Hardacker, RN, MSN; Jennifer Hebert-Beirne, PhD; Missy Lavender, MBA; David Shoham, PhD; Alayne D. Markland, DO, MSc; Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM; Kathryn L. Burgio, PhD; Cora E. Lewis, MD; Gerald McGwin, PhD; Camille P. Vaughan, MD, MS; Beverly R. Williams, PhD; Emily S. Lukacz, MD; Sheila Gahagan, MD, MPH; Daphne Y. LaCoursiere, MD, MPH; Jesse Nodora, DrPH; Janis M. Miller, PhD, MSN; Lawrence Chin-I An, MD; Lisa Kane Low, PhD, MS, CNM; Diane K. Newman, DNP, CRNP; Amanda Berry, MSN, CRNP; C. Neill Epperson, MD; Heather Klusaritz, PhD, MSW; Kathryn H. Schmitz, PhD; Ariana L. Smith, MD; Ann E. Stapleton, MD; Jean F. Wyman, PhD; Siobhan Sutcliffe, PhD; Aimee S. James, PhD; Jerry Lowder, MD, MSc; Melanie R. Meister, MD, MSCI: Leslie M. Rickey, MD; Deepa Camenga, MD, MS; Shayna D. Cunningham, PhD; Jessica Lewis, PhD.; Tamara G. Bavendam MD, MS; Bernard L. Harlow, PhD and Kyle Rudser, PhD; Sonya S Brady, PhD; John Connett, PhD; Haitao Chu, MD, PhD; Melissa L. Constantine, PhD, MPaff; Cynthia S. Fok, MD, MPH; Todd Rockwood, PhD; Mary H. Palmer, PhD, RN. Funding Information: There are no financial conflicts directly related to this work. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) by cooperative agreements [grants U01DK106786, U01 DK106853, U01 DK106858, U01 DK106898, U01 DK106893, U01 DK106827, U01 DK106908, U01 DK106892]. Additional funding from: National Institute on Aging, NIH Office of Research on Women{\textquoteright}s Health and the NIH Office of Behavioral and Social Sciences Research. NIH Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12905-020-01136-w",

language = "English (US)",

volume = "21",

journal = "BMC Women's Health",

issn = "1472-6874",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Rationale and design of the validation of bladder health instrument for evaluation in women (VIEW) protocol

AU - For the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium

AU - Lukacz, Emily S.

AU - Constantine, Melissa L.

AU - Kane Low, Lisa

AU - Lowder, Jerry L.

AU - Markland, Alayne D.

AU - Mueller, Elizabeth R.

AU - Newman, Diane K.

AU - Rickey, Leslie M.

AU - Rockwood, Todd

AU - Rudser, Kyle

N1 - Funding Information: The PLUS Research Consortium (aka Group Authorship) consists of the following members who contributed to this work. Linda Brubaker, MD, MS; Elizabeth Mueller, MD, MSME; Colleen Fitzgerald, MD, MS; Cecilla Hardacker, RN, MSN; Jennifer Hebert-Beirne, PhD; Missy Lavender, MBA; David Shoham, PhD; Alayne D. Markland, DO, MSc; Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM; Kathryn L. Burgio, PhD; Cora E. Lewis, MD; Gerald McGwin, PhD; Camille P. Vaughan, MD, MS; Beverly R. Williams, PhD; Emily S. Lukacz, MD; Sheila Gahagan, MD, MPH; Daphne Y. LaCoursiere, MD, MPH; Jesse Nodora, DrPH; Janis M. Miller, PhD, MSN; Lawrence Chin-I An, MD; Lisa Kane Low, PhD, MS, CNM; Diane K. Newman, DNP, CRNP; Amanda Berry, MSN, CRNP; C. Neill Epperson, MD; Heather Klusaritz, PhD, MSW; Kathryn H. Schmitz, PhD; Ariana L. Smith, MD; Ann E. Stapleton, MD; Jean F. Wyman, PhD; Siobhan Sutcliffe, PhD; Aimee S. James, PhD; Jerry Lowder, MD, MSc; Melanie R. Meister, MD, MSCI: Leslie M. Rickey, MD; Deepa Camenga, MD, MS; Shayna D. Cunningham, PhD; Jessica Lewis, PhD.; Tamara G. Bavendam MD, MS; Bernard L. Harlow, PhD and Kyle Rudser, PhD; Sonya S Brady, PhD; John Connett, PhD; Haitao Chu, MD, PhD; Melissa L. Constantine, PhD, MPaff; Cynthia S. Fok, MD, MPH; Todd Rockwood, PhD; Mary H. Palmer, PhD, RN. Funding Information: There are no financial conflicts directly related to this work. This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH) by cooperative agreements [grants U01DK106786, U01 DK106853, U01 DK106858, U01 DK106898, U01 DK106893, U01 DK106827, U01 DK106908, U01 DK106892]. Additional funding from: National Institute on Aging, NIH Office of Research on Women’s Health and the NIH Office of Behavioral and Social Sciences Research. NIH Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Background: Bladder health is an understudied state and difficult to measure due to lack of valid and reliable instruments. While condition specific questionnaires assess presence, severity and degree of bother from lower urinary tract symptoms, the absence of symptoms is insufficient to assume bladder health. This study describes the methodology used to validate a novel bladder health instrument to measure the spectrum of bladder health from very healthy to very unhealthy in population based and clinical research. Methods: Three samples of women are being recruited: a sample from a nationally representative general population and two locally recruited clinical center samples—women with a targeted range of symptom severity and type, and a postpartum group. The general population sample includes 694 women, 18 years or older, randomly selected from a US Postal delivery sequence file. Participants are randomly assigned to electronic or paper versions of the bladder health instrument along with a battery of criterion questionnaires and a demographic survey; followed by a retest or a two-day voiding symptom diary. A total of 354 women around 7 clinical centers are being recruited across a spectrum of self-reported symptoms and randomized to mode of completion. They complete the two-day voiding symptom diary as well as a one-day frequency volume diary prior to an in-person evaluation with a standardized cough stress test, non-invasive urine flowmetry, chemical urine analysis and post void residual measurement. Independent judge ratings of bladder health are obtained by interview with a qualified health care provider. A total of 154 postpartum women recruited around 6 of the centers are completing similar assessments within 6–12 weeks postpartum. Dimensional validity will be evaluated using factor analysis and principal components analysis with varimax rotation, and internal consistency with Cronbach’s alpha. Criterion validity will be assessed using multitrait-multimethod matrix including correlations across multiple data sources and multiple types of measures. Discussion: We aim to validate a bladder health instrument to measure the degree of bladder health within the general population and among women (including postpartum) recruited from local clinical centers. Trial registration NCT04016298 Posted July 11, 2019 (https://www.clinicaltrials.gov/ct2/show/NCT04016298?cond=bladder+health&draw=2&rank=1).

AB - Background: Bladder health is an understudied state and difficult to measure due to lack of valid and reliable instruments. While condition specific questionnaires assess presence, severity and degree of bother from lower urinary tract symptoms, the absence of symptoms is insufficient to assume bladder health. This study describes the methodology used to validate a novel bladder health instrument to measure the spectrum of bladder health from very healthy to very unhealthy in population based and clinical research. Methods: Three samples of women are being recruited: a sample from a nationally representative general population and two locally recruited clinical center samples—women with a targeted range of symptom severity and type, and a postpartum group. The general population sample includes 694 women, 18 years or older, randomly selected from a US Postal delivery sequence file. Participants are randomly assigned to electronic or paper versions of the bladder health instrument along with a battery of criterion questionnaires and a demographic survey; followed by a retest or a two-day voiding symptom diary. A total of 354 women around 7 clinical centers are being recruited across a spectrum of self-reported symptoms and randomized to mode of completion. They complete the two-day voiding symptom diary as well as a one-day frequency volume diary prior to an in-person evaluation with a standardized cough stress test, non-invasive urine flowmetry, chemical urine analysis and post void residual measurement. Independent judge ratings of bladder health are obtained by interview with a qualified health care provider. A total of 154 postpartum women recruited around 6 of the centers are completing similar assessments within 6–12 weeks postpartum. Dimensional validity will be evaluated using factor analysis and principal components analysis with varimax rotation, and internal consistency with Cronbach’s alpha. Criterion validity will be assessed using multitrait-multimethod matrix including correlations across multiple data sources and multiple types of measures. Discussion: We aim to validate a bladder health instrument to measure the degree of bladder health within the general population and among women (including postpartum) recruited from local clinical centers. Trial registration NCT04016298 Posted July 11, 2019 (https://www.clinicaltrials.gov/ct2/show/NCT04016298?cond=bladder+health&draw=2&rank=1).

KW - Bladder

KW - Health

KW - Instrument

KW - Measurement

KW - Questionnaire

KW - Scale

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=85098950152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85098950152&partnerID=8YFLogxK

U2 - 10.1186/s12905-020-01136-w

DO - 10.1186/s12905-020-01136-w

M3 - Article

C2 - 33413284

AN - SCOPUS:85098950152

SN - 1472-6874

VL - 21

JO - BMC Women's Health

JF - BMC Women's Health

IS - 1

M1 - 18

ER -

Rationale and design of the validation of bladder health instrument for evaluation in women (VIEW) protocol

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this